Semaglutide Use in Normal Weight Patients for Fitness Purposes

FDA-Approved Indications and Patient Selection Criteria

The FDA has approved semaglutide 2.4 mg specifically for chronic weight management only in patients meeting strict BMI criteria, including a BMI ≥30 kg/m² or a BMI ≥27 kg/m² with at least one weight-related comorbidity, as stated by the American College of Gastroenterology 1, 2
Normal weight patients do not meet these criteria and fall outside the approved indication, according to the American Gastroenterological Association 1

All major clinical trials, including the STEP trials and SELECT trial, specifically enrolled only patients with overweight or obesity, with a mean baseline BMI ranging from 32.0 to 39.9 kg/m² and a mean baseline weight ranging from 86.9 to 113.2 kg, as reported by the American Gastroenterological Association 2
No safety or efficacy data exists for normal weight individuals, as stated by the American College of Gastroenterology 2

Semaglutide causes substantial weight loss, which in normal weight individuals would result in potentially dangerous underweight status, according to the American Gastroenterological Association 2
Semaglutide may cause loss of lean body mass without concurrent resistance training, as reported by the American College of Sports Medicine 3
Pooled data from 8 RCTs demonstrated a 38% higher risk of serious adverse events with semaglutide versus placebo, including pancreatitis, acute gallbladder disease, and severe gastrointestinal complications, as stated by the American Gastroenterological Association 2

Semaglutide is contraindicated in patients with a history of pancreatitis, according to the American College of Gastroenterology 2

The risk-benefit ratio is unacceptable in normal weight patients, with no demonstrated benefit and significant harms, including a 38% increased risk of serious adverse events and substantial GI side effects, as stated by the American Gastroenterological Association 2
The cost of semaglutide without insurance coverage is a significant consideration, as reported by the American College of Gastroenterology 3